AstraZeneca over US$3.5 billion and Ionis to develop a new antisense oligonucleotide drug under development

On December 7, AstraZeneca and Ionis Pharmaceuticals (hereinafter referred to as "Ionis") announced that an antisense oligonucleotide (ASO) eplontersen (IONIS-TTR-LRX) of the latter under development has reached over 35.

According to the terms of the agreement, the two parties will jointly develop and commercialize eplontersen in the United States, and AstraZeneca will obtain the right to develop and commercialize eplontersen in regions other than Latin America

Amyloid transthyretin cardiomyopathy (ATTR-CM) is a systemic, progressive, and fatal disease that can lead to progressive heart failure and death within 4 years of diagnosis

Eplontersen is a ligand-coupled antisense oligonucleotide therapy under development, which aims to reduce the production of transthyretin (TTR) protein to treat all types of transthyretin-mediated amyloidosis (ATTR)

Reference materials:

[1] AstraZeneca and Ionis sign deal to develop and commercialise eplontersen.

(The original text has been deleted)